CMV Immunoglobulin (IV)

CMV Immunoglobulin (IV)

Presentation

Single vials each containing 1.5 million units of CMV immunoglobulin activity.

Indications for Use

• Prevention of CMV infection in bone marrow, renal, cardiac and liver transplant recipients who are CMV antibody negative where the donor is CMV antibody positive.
• Treatment of established CMV infection (e.g. CMV pneumonia, renal parenchymal infection) in association with virucidal treatment (e.g.ganciclovir).

Contraindications

Contraindicated in individuals with:

• A true anaphylactic reaction to a human immunoglobulin
• IgA deficiency – unless they have no circulating anti IgA antibodies.

Precautions

• Aseptic meningitis syndrome (AMS): occurs infrequently in association with intravenous immunoglobulin treatment; occurring within several hours to two days following treatment.
• Occasional reports of renal dysfunction and acute renal failure, mainly with sucrose containing preparations. This product does not contain sucrose.

Availability

Requests to ARCBS.

Dosage and Administration

Because there is currently no international standard for CMV Immunoglobulin, recommended dosages remain empirical.

• Prophylaxis - 25,000 units/kg on days -4, -2, on the day of transplantation and then weekly for a further 2 months.
• Therapy - 50,000 units/kg initially, repeated after 4-5 days and then every 10-14 days until clinical improvement occurs.

The product s does not contain antimicrobial preservative; it must be used immediately after opening the vial.

MUST be administered intravenously only. May be infused undiluted. Allow to reach room temperature prior to infusion.

Administered by slow intravenous infusion. Commence infusion at 1ml / minute and gradually increase to a maximum of 3 to 4 mls/min if tolerated by the patient. Monitor vital signs closely prior to and through out infusion.

Administer separately from other intravenous infusions or medications.

Refer to the current product information sheet for further information.